ZolidPioglitazone

Our Objective is to make

Zolidnumber 1 Glitazone in Pakistan

1

IMS Analysis Total Antidiabetic Market

I.M.S Data Analysis - 1st Quarter 2007 Total Anti Diabetic MarketSegment Total Antidiabetics A10 Oral Antidiabetics A10B Sulphonylureas A10B1 Biguanides A10B2 SU +Big A10B3 Glitazones A10B4 Glitazone +other Oral Antidiabetics A10B 8 Glucosidase inh A10B5 Other A10B9 Products 144 114 66 14 9 20 Units 20,733,200 18,550,100 10,640,000 5,021,200 843,200 1,795,000 Value Rs. 2,605,035,000 1,789,011,000 1,186,530,000 283,827,000 61,552,000 214,452,000 share 3.1% 69% 66.3% 16% 3.4% 12% Gr.% 4% 15% 10% 7% 122% 45%

1 1 3

24,800 191,900 34,000

2,787,000 29,492,000 10,370,000

0.2% 1.6% 0.6% 8% -13%

Human Insulins A10C Animal Insulins A10D

26 4

1,887,800 294,900

777,837,000 38,187,000

30 2

-13% -5%

2

Zolid IMS Data Analysis Qtr 1 2007Thiazolidinedione Market SegmentTZDs A10B4 No of products 20

Units1,795,000

Value Rs214,452,000

Mkt share12%

Gr%45%

ProductPiozer

Strengths and Pack sizes14s

Unit CompanyHilton 680,800

Value Rs. Share73,201,000 34

Gr %25

PioglitazoneZolid 14s Getz 438,100 54,208,000 25 38

PioglitazoneAvandia Rosiglitazone Nelizig Rosiglitazone Glitos 20s Highnoon 173,100 15,964,000 7 670 14s GSK 24,800 24,255,000 11

-12

14s

WRP

94,100

9,956,000

5

519

PioglitazoneBlutab 10s WRP 110,000 8,219,000 4 74

RosiglitazoneDiacto Pioglitazone Rosita Rosiglitazone Gliden Pioglitazone Poze Pioglitazone Piokure 14s Helix 23,800 3,261,000 2 10s PV 68,600 5,220,000 2 455 14s C.C 60,100 8,082,000 4 76

-4

14s

AGP

22,800

2,309,000

1

14s

Kut

25,700

2,238,000

1

4

PioglitazoneOrnix Rosiglitazone 10s Martin Dow 22,500 1,756,000 1 37

3

Zolid IMS Data Analysis Qtr 1 2007Thiazolidinedione Market Mkt share12%

SegmentTZDs A10B4 No of products 20

Units1,795,000

Value Rs214,452,000

Gr%45%

ProductDowglit

Strengths and Pack sizes14s

Unit CompanyMDW 14,400

Value Rs. Share1,554,000 1 Gr %

PioglitazoneFantasia 14s WSH 9,800 1,248,000 1 120

PioglitazonePiofit 20s Schazoo 5,700 947,000 0

Pioglitazone Dizone Pioglitazone Pyctos PioglitazoneGlyrol 14's H&K 8,300 765,000 0

14's

Highnoon

6,100

722,000

0

14s

MDS

4,800

507,000

0

-51

Pioglitazone Pio A PioglitazoneEscort Rosiglitazone 20's EV 2 1,600 256,000 0

10's

STH

-

1,000

-

4

Zolid IMS Data Analysis 1Q 2007PIOGLITAZONE MARKETUnits 1,396,000 No of products 14 Rank 1 Product Value Rs. 159,254,000 Strength s and Pack sizes

Company

M.R.P

Lanch date

Units

Value Rs.

MarketS hare%

G LY O %

Piozer Pioglitazone

Hilton 15 mg 30 mg 45 mg Getz 15 mg 30 mg 45 mg Searle 15 mg 30 mg 45 mg CCL 15mg 30 mg 45mg Helix 15mg 30 mg 45mg AGP 15 mg 30 mg 45 mg Kut 15 mg 30 mg 45 mg 70 133 182 5-Mar 5-Mar 5-Mar 74 142 187 7-Feb 7-Feb 7-Feb 70 265 182 5-Jun 5-Jan 5-Jun 83.3 142.8 190.4 5-Jul 5-Jul 5-Jul 84 147 196 6-Jan 6-Jan 6-Jan 98 168 224 Oct.04 Oct.04 Oct.04 84 147 196 Aug,04 Aug,04 Aug,04

680,800 290,500 301,700 88,600 438,100 183,300 201,100 53,700 94,100 43,100 38,700 12,300 60,100 19,700 26,500 14,000 23,800 10,700 8,000 5,100 22,800 10,700 8,200 3900 25,700 14,800 7,900 3,000

73,201,000 20,744,000 37,701,000 14,757,000 54,208,000 15,265,000 28,713,000 10,230,000 9,956,000 3,078,000 4,828,000 2,050,000 8,082,000 1,641,000 3,778,000 2,663,000 3,261,000 638,000 1,842,000 782,000 2,309,000 684,000 998,000 627000 2,238,000 871,000 897,000 470,000

46.0 28 51.5 20.2 34.0 28.2 53 18.9 6.330.9 48.5 20.6

25 24 26 26 38 24 39 61519 517 600 389

2

Zoild Pioglitazone

3

Glitos Pioglitazone

4

Diacto Pioglitazone

5.1 20.3 46.7 332.05 19.6 56.5 24 1.45 29.6 43.2

76 42 81 98 -4.0 34 -21 35

5

Gliden Pioglitazone

6

Poze Pioglitazone

27.2 1.4 38.9 40.1 21 4 21 3 -16

7

Piokure Pioglitazone

5

Zolid IMS Data Analysis 1Q 2007Units 1,396,000 No of products 14 Rank 8 Product Value Rs. 4,402,000 Strength s and Pack sizes

Company

M.R.P

Lanch date

Units

Value Rs.

MarketSha re%

G LY O %

DowglitPioglitazone

MDW 15 mg 30 mg 45 mg Wsh 15 mg 30 mg 45 mg Schazoo 30 mg 45 mg Healthtec 15 mg 30 mg 45 mg Highnoon 15 mg 30 mg 45 mg Jan-07 Jan-07 Jan-07 70 132 176 6-May 6-May 6-May 180 240 6-May 6-May 98 168 224 5-Sep 5-Sep 5-Sep 6-Aug 6-Aug 6-Aug

14,400 5,600 6,400 2,400 9,800 4,300 3,200 2,300 5,700 4,200 1500 8,300 4,000 3100 1,200 6100 2100 2300 1700 4,800 2,100 1,700 1,100 1,600 1,000 300 300

1,554,000 397,000 755,000 402,000 1,248,000 359,000 457,000 432,000 947,000 635,000 313,000 765,000 237,000 346,000 182,000 722,000 149,000 294,000 279,000 507,000 142,000 197,000 169,000 256,000 125,000 58,000 73,000 25.6 48.6 25.8

56

9

Fantasia Pioglitazone

28.8 36.6 34.5

120 215 101 92

10

Piofit Pioglitazone

67 33

11

Dizone Pioglitazone

31 45.2 23.8

12

Pyctos

20.7 40.6 38.7 -51 -46 -60 -40

13

Glyrol Pioglitazone

MDS 15 mg 30 mg 45 mgEV 2

80 140 185

4-Dec 4-Dec 4-Dec

27.9 38.8 33.3

14

Pio A

Pioglitazone

15 mg 30 mg 45 mg

Jan-06 Jan-06 Jan-06

48.8 22.8 28.4

6

MARKET ANALYSIS The total antidiabetic market A10 is one of the growing markets with almost 20.7 million units and its value is 2.6 bio with growth of 4%. Oral anti diab A10B is 1.789 bio with 15% growth. Human Insulin A10C is 778 mio with -13% growth. Animal Insulin A10D is 38 mio with -5% growth.

Oral antidiab has 114 products, with Sulphonylureas being the most prominent group having almost 66% share of OADs followed by Biguanides having 16% share. Glitazones now a well established group has 214 mio value with 12% share but as the concept of insulin resistance & insulin sensitizers is further increasing this group is sure to grow more tremendously. Glitazones are showing the highest growth in Anti-diabetic market with 45%. In Glitazone market, both Piozer & Zolid are among the top glitazone followed by Avandia. Piozer is the market leader having 34% share followed by Zolid having 25% share. Analyzing Pioglitazone market currently Piozer has 73 mio value &46 % share of Pioglitazone market followed by Zolid having 54 mio value & 34% share. This is followed by Glitos of Searle and Diacto of CCL. But if we analyze the whole TZD market, then there is Nelizig of High Noon and Blutab of Werrick. As FDA has warned about the use of Rosiglitazone, so we should foucus in this quarter to get maximum patients from Rosiglitazone like Avandia, Nelizig and Blutab. After FDA alert, we must have to be very vigilant from our competitors in anti diabetic market. They would try to present to doctors that if safety issue is coming with Rosiglitazone than it would also be with Pioglitazone (Class Effect). But we have distributed the study of NEJM which claims that there is no class effect with Pioglitazone.

New Products Launched In Q1 2007:

7

Sales Analyzer of ZolidSales Analyzer of Zolid gives us idea about ther market and comparision of Zolid with sulphonylureas as well as with Glitos and Nelizig. We will now onward use this tool for our analysis and planning with better idea. In this quarter, we will especially focus to the areas in which Rosiglitazone like Nelizig is moving fast. Our objective is to convert the patients of Rosiglitazone after the news from FDA regarding its safety.

National:Sales analyzer on national level shows that Zolid is having 7.96% share, Nelizig is having 3.28, while Glitos is 2.03% and Diacto is 1.03%. When comparing with sulphonylurea, Dimicron is on top position with 35.94 share and Amaryl with 18.75%.

South:Sales analyzer of south shows that Zolid is having share of 9.57%, Nielizig is with 2.62% and Glitos is with 2.16%. So both these glitazones should be closely observed on brick level. In suphonylurea market, major competition is with Diamicron as it is 28.39% and then Amaryl 20.81%.

Central:Central is having Zolid share of 6.8% and Nelizig should be monitored as it is carrying share of 3.29%. In sulphonylureas, Diamicron is the player that should be knocked out as it is about 39% and Amaryl has 20.36%.

North:North is having almost the same situation as that of central. Zolid is with 9.32% , Nelizig with 2.9%, Glitos with 1.93%. Diamicron is again doing wonder in North with share of 34.35% and immediately should be focused.

8

Sales AnalysisZOLID AreaKARACHI 1 KARACHI 2 HYDERABAD SUKKUR QUETTA SOUTH FAISALBAD GUJRANWALA LAHORE MULTAN SAHIWAL CENTRAL RAWALPINDI PESHAWER SWAT NORTH

Jan-Mar 2007 YTD Ach Yield/TM(000)111 98 94 95 115 102 96 97 109 114 84 102 104 105 75 101 102 166 124 75 92 80 116 88 97 105 70 85 90 103 62 38 78 95

Pakistan

Karachi 1 has achieved the highest yield/TM followed by Karachi 2. But the very encouraging aspect is that Lahore has come up on 3rd position in Q1. On regional basis, South region is leading with the highest yield/TM, central is on 2 nd and north is on 3rd position and all the 3 regions have achieved their YTD budget. Yield of Hyderabad, Quetta, Multan, Peshawar and Swat are not up to the mark. North region (Swat & Peshawar come up colleagues, in this quarter. Congratulations to Karachi 1, Quetta, Lahore, Multan, Rawalpindi and Peshawar to achieve their quarter 1st budget. We hope so that Lahore will give tough time to Karachi for 1st and 2nd positions. The results of Quarter 1st are very motivating and we would get more successes by planning and executing innovative scientific activities for Zolid.

9

Zolid Top Guns for Qtr 1 2007

Rank 1 2 3 4 5 6 7 8 9 10

Name Syed Zeeshan Haider Aamir Ali Muhammad Nadeem Ansari Anjum Riaz Babar Khursheed Butt Rafeh Ali Abdul Mueen Faisal Mehmood Azhar Ali Zafar Iqbal

Area Karachi 1 Karachi 2 Karachi 1 Rawalpindi Gujranwala Karachi 1 Karachi 1 Lahore Sukkur Lahore

Karachi 1 is again having the maximum Top number in Top 10 Guns. So congratulations Syed Zeeshan Haider as he has proven himself and snatched the position from Nadeem Ansari after a very long time. Amir and Nadeem, you both strive to get the 1st position. It is very healthy sign to see 2 colleagues, Faisal Mehmood and Zafar Iqbal from Lahore. Now the challenge for North as Anjum Riaz is one representing the whole region.

10

THEME: Managing Diabetes Is Our Job # 1 POSITIONINGZolid, for enhanced glycemic control

TARGET DOCTORSDiabetologists Physicians Cardiologists Potential GPs

ObjectiveQUALITATIVE OBJECTIVECreating awareness about Insulin resistance disease concept and establishing the role of Zolid in providing excellent glycemic control in type 2 diabetes mellitus. Highlighting superiority of Zolid (Pioglitazone) over rosiglitazone in improving lipid profile of patients.

QUANTITATIVE OBJCTIVETo achieve 100% budget of 2007. To achieve 35% share of TZD market by the end of year 2007.

CURRENT SITUATION Key FactDoctors by and large are still not clear with the use of glitazones. Only Getz and Hilton are doing academic activities, other players have not worked in the development of concept.

PROMOTIONAL STRATEGYTo increase the prescriber base of Zolid by creating awareness about Insulin resistance disease concept and the use of glitazones. To establish the role of Zolid in providing excellent glycemic control in type 2 diabetes mellitus. Highlighting superiority of Zolid (Pioglitazone) over rosiglitazone in improving lipid profile of patients.

11

PROMOTIONAL PLAN FOR Q3 2007 1. Diabetes Management WorkshopOBJECTIVE To increase the prescriber base of Zolid by establishing the concept of Insulin Resistance. TARGET AUDIENCE GPs NO. OF DOCTORS 25-30 per workshop SPEAKERS Will be arranged locally. SCHEDULE South R.Yar Khan No 1 Central Lahore Faisalabad Sialkot Gujrat Gujranwala DG Khan No 2 1 1 1 1 1 North Rawalpind i Swat Peshawar No 1 1 1

Total11 workshops in Q3 2007.

12

2. Zolid- Safety PresentationsOBJECTIVE To present and highlight safety profile of Pioglitazone to GPs/MOs by giving them a brief presentation and studies handouts. TARGET AUDIENCE Potential GPs/MOs of Medicine who are reluctant to prescribe Pioglitazone due to their doubts in safety of the molecule. NO. OF DOCTORS 5-7 doctors/ Presentation SPEAKER Preferably ASM or locally arranged BUDGET Rs. 2000/ Presentation PRESENTAION ALLOCATION As discussed with ASMs South Karachi 1 Karachi 2 Hyderabad Sukkur Quetta Total No 8 8 8 5 3 32 Central Lahore Faisalabad Multan Sahiwal Gujranwala Total No 8 6 6 4 4 28 North Rawalpindi Swat Peshawar Total No 10 4 8 22

Total 82 Safety Presentations planned in Q3 2007.

13

3. Diabetic OPD SittingsOBJECTIVE Building and encashment of relations in permanent diabetic OPDs of institutions. TARGET AUDIENCE MOs/Drs of permanent diabetic OPDs. METHODOLOGY This sitting will be done only in permanent diabetic OPDs. Our colleagues having permanent diabetic OPD in their territory will be provided extra samples and budgets for this sitting. Our colleague will arrange such sitting by providing samples, diet charts and by arranging tea of the OPD by the given budget. Every colleague having permanent OPD will do this activity once in a week or as per response of the activity. BUDGET Rs. 250/ Sitting One sitting/Week PERMANENT DIABETIC OPDS DATA: As discussed with ASMs South Karachi 1 Karachi 2 Hyderabad Sukkur Quetta Total No 4 3 2 2 -11 Central Lahore Faisalabad Multan Sahiwal Gujranwala Total No 4 1 2 ----7 North Rawalpindi Swat Peshawar Total No 6 --1 7

Total permanent diabetic OPDs = 25 25x4 x3 = 300 sittings are planned in Q3 2007.

14

4. Study Reprint:In Q 3 2007, we will distribute study reprint Metabolic and Histologic Improvements in Non-Alcoholic Steatohepatitis (NASH) During Pioglitazone Treatment is Associated with a Reduction in Inflammatory Markers. Background: NASH is a chronic liver disease and is characterized histologically by fatty liver. NASH is associated with obesity, insulin resistance, systemic inflammation and type 2 diabetes. Pioglitazone is a PPAR Gamma receptor agonist has shown to be effective in insulin resistance. The patients with NASH showed significant metabolic and histologic improvement with the treatment with Pioglitazone. This study poster was presented in ADA 2006 Contents: This Poster has complete summary of study Aim, methods, design, summary of clinical and lab parameter changes, summary of histological results and conclusions. We will also provide the full text of this study for your refernce. Summary: Two groups of patients were formulated. One was placebo (21 patients) and the other (26 patients) was on Pioglitazone. This study was of 28 weeks. Pioglitazone 30 mg/day was given for first 8 weeks and then patients were shifted to Pioglitazone 45mg for remaining 20 weeks. Treatment of NASH patients with Pioglitazone led to a reduction in hepatic fat content and normalizing of liver enzymes with an improvement in glucose metabolism, lipid metabolism and histopathology. Quantity per TM 20 Study reprints with full text/TM will be given. This study should be distributed in Gastroenterologists and Physicians. It is highly recommended that all colleagues should discuss this study in detail with ASM before its distribution. 15

5. Other Promotional toolsDIABETES DETECTION DAYS (3D ACTIVITY),75 strips /TM/month DIET CHARTS, PATIENT RECORD BOOKS, 3D POSTERS SOCIAL EVENTS Combined with other products.

DETAIL AID4 page literature highlighting Guide for PROACTIVE Study and highlighting the better efficacy of Zolid over sulphonylureas.

Model Detailing pattern

For Lit 2Q 07 Highlighting PROACTIVE Study and Superior efficacy of Zolid as compared to sulphonylureas in maintenance of HbA1c and prevention of secondary failure Page 1 (Title) Dr Sb today I share with you the increasing prevalence of diabetes in Pakistan. In 2003, the diabetic population was 6.2 million and in 2025 it would be 11.6 millions in Pakistan. Dr Sb it will become double in 2025. So Dr Sb in this scenario, Managing Diabetes in our Job #1, . Page2 (PROACTIVE STUDY) Dear. Dr. Today I will only discuss with you landmark study PROACTIVE i.e. Prospective Pioglitazone Clinical Trial in Macro vascular Events. This study proved that pioglitazone proved the sustained glycemic response in terms of HbA1c. There were 2 groups of patients one was on pioglitazone and other was placebo. In 36 months, the patients on pioglitazone had better HbA1c as compared to placebo group. The cardiovascular results showed reduction in cardiovascular morbidity and mortality (pointing towards graph) with pioglitazone group than in placebo group. So the cardiovascular results can be summarized that 16

Pioglitazone can reduce macro vascular events With 10% relative risk reduction in primary end point And 16% relative risk reduction in the secondary end point. i.e. All cause mortality, MI & Stroke. Page 3 Piolglitazone showed superior glycemic control in terms of HbA1c when compared with sulphonylureas. This study is of 3.5 year and total patients were 500 with 8.5 HbA1c. After completion of the study the HbA1c in sulphonylurea group was 8.5 but with pioglitazone it reduced and maintained at 8.0. Similarly the same study also proved that with pioglitazone the mean annual progression rate to insulin (secondary failure) was 6.55% and with sulphonylurea it was 16.44%. So this study clearly proved the superiority of pioglitazone over the sulphonylureas.

Page 4 (Back page) Therefore Dr. Pioglitazone is very beneficial for your diabetic patients as it decreases the resistance thus provides effective glycemic control. As it acts on peripheral level thus reduces the insulin resistance and so preserves the pancreas of the patient. Zolid improves the lipid profile of the patient so reduces the cardiovascular events. With zolid there are less chances of hypoglycemia so provides comfort to patients. Once daily dosage provides convenience to your patients. As you know we have Zolid, the first pioglitazone in Pakistan. It is available in three strengths -------. Dr. I am confident that keeping in view of the benefits of Zolid you will prescribe Zolid in your diabetic patients.

17

Rovista(Rosuvastatin)

18

IMS Statins Analysis-4Q 06

Cholesterol/Triglyceride Regulator Market

Statins95.0%

930 Mio Growth 26%

1.3% 3.7%

Fibrates

Others

19

Statins IMS Data Analysis - 1st Qtr 2007Segment Total Mkt C holest. regulators C 10A U nits N o of products 95 5,908,500 979,267,000100

Value Rs. Share% Gr.%

0

Total Market Statins C 10A1 N o of products 86 5,615,900 931,375,000 95 0 Strengths and Pack R ank B R AN D (R ank) siz es C ompany Unit Value Rs. Share % G r. % 1 Lipiget Tabs 10 , 20, 40 mg Getz 954,000 163,949,000 18 50 Atorvastatin 10's 2 Survive Tabs 10 , 20, 40 mg W errick 696,500 113,615,000 12 9 Simvastatin 10's 3 Zocor Tabs 10 , 20, 40 mg MSD 237,700 98,120,000 11 14 Simvastatin 10's P fizer 4 Lipitor Tabs 10 , 20, 40 mg 118,600 87,299,000 9 16 A torvastatin 10's 5 Lipirex Tabs 10 , 20, 40 mg HighNoon 450,100 52,860,000 6 39 A torvastatin 10's 6 Atorva Tabs 10 , 20 mg Pharm atec 165,900 33,762,000 4 71 Atorvastatin 10's 7 Lescol C aps 20 , 40, 80 mg Novartis 39,900 29,304,000 3 10 Fluvastatin 28's -6 8 Prostatin Tabs 10 , 20, 40 mg CCL 160,800 28,489,000 3 A torvastatin 10's 9 Simvaz af Tabs 10 , 20 mg Zafa 441,100 26,408,000 3 61 Simvastatin 10's -9 10 R ecol Tabs 10 , 20 mg Barrett Hodgson 74,800 17,603,000 2 Simvastatin 10's 11 Simva Tabs 10 , 20 mg Nabi Q asim 253,000 17,200,000 2 9 Simvastatin 10's -2 12 Eglocard Tabs 10 , 20, 40 mg Him ont 93,400 14,933,000 2 Simvastatin 10's 13 Limitrol Tabs 10 , 20, 40 mg Pharm evo 100,900 13,029,000 2 9 Simvastatin 10's, 5's , 5's. 18 R olip Tabs 5 , 10, 20 mg Hilton 73,000 10,284,000 1 Rosuvastatin 10's 19 R ovista Tabs 5 , 10, 20 mg Getz 72,700 94,480,00 1 Rosuvastatin 10's 25 X-Plended Tabs 5 , 10, 20 mg Pharm evo 58,600 7,422,000 1 Rosuvastatin 10's 20

Fibrates C10A2Segment C10A2 FibratesNo of products 2

Units 109,300 CompanyAtco Efroze

Value Rs. Share 12,356,000 100 Value Rs.11,648,000 708,000

Gr.% 20% Gr. %23 -11

BRAND Gempid Lipocor

Unit87,200 13,400

Share94.3 5.7

CHOLESTEROL & TRIGLYCERIDE REDUCING AGENTS Rovista belongs to lipid lowering agents market. Cholesterol lowering agents are classified in to 3 categories: Statins, Fibrates and Cholesterol Absorption Inhibitors. Statins dominate the cholesterol lowering drug market having 95% share.

STATINS MARKET ANALYSISThe total market of statins in Pakistan is around 5.9 million in units and Rs. 979 million in turnover. The market reflects a healthy growth of 24% over last year. Lipiget (Atorvastatin) has successfully maintained the no.1 position with a value of 163.9 million and a growth of 50%. Lipiget enjoys the market share of 18% Survive (Simvastatin) product of M/s. Werrick is the 2nd in line with a growth of 9%, turnover Rs. 113 million and a market share of 12%. Zocor (simvastatin) launched by M/s. MSD is on the 3rd position; has a turnover of Rs. 98 million and with 11% market share and 14% growth.

ROSUVASTATIN MARKETCurrently there are 3 brands for Rosuvastatin in the market. Rolip (Rosuvastatin), launched by Hilton is ranked 18 by the IMS and generated a turnover of Rs. 10.2 million with a market share of 1%. Rovista has value of Rs. 9.44 million and having market share of 1%. Xplended (Rosuvastatin), launched by Pharmevo is ranked 25 by IMS and generated a turnover of Rs. 7.42 million with a market share of 1%. 21

SALES ANALYSISRovista Area Jan-Mar 2007 YTD Ach Yield/TM(000)173 125 183 118 151 163 81 149 113 105 176 102 157 134 53 126 130

KARACHI 1 KARACHI 2 HYDERABAD SUKKUR QUETTA SOUTH FAISALBAD GUJRANW ALA LAHORE MULTAN SAHIW AL CENTRAL RAW ALPINDI PESHAW ER SW AT NORTH

Pakistan

53 40 57 28 44 45 21 17 29 27 34 25 37 35 17 33 34

National achievement of Rovista is marvelous and it is 130% YTD. On regional basis, south is on first position with 163% achievement and Rs. 45,000/TM. Swat and Faisalabad are the only 2 areas that could not achieve the budget, colleagues come up with winning spirit. Yield/TM of Swat, Faisalabad, Gujranwala and Multan are not above or equal to the national yield so they must focus to meet the national yield. Overall, we all are doing very well for Rovista. We have analyzed and reviewed our objective for Rovista. Now we all will strive for 7th rank in IMS instead of 8th in first year after the launch.

22

ROVISTA KINGSTop Ten TMs of Qtr 4 2006Rank 1 2 3 4 5 6 7 8 9 10 Name Amir Ishtiaq Rao Sanaullah Khan Zulfiqar Ali Wasan Anjum Riaz Aamir Ali Abdul Mueen Rafeh Ali Muhammad Ansari Waqar Ahmad Nadeem Area Hyderabad Karachi 1 Hyderabad Rawalpindi Karachi 1 Karachi 1 Karachi 1 Karachi 1 Hyderabad Peshawar

Syed Adnan Jamshaid

Heartiest congratulations to Amir Ishtiq for maintaining his position in King club. It is cleared that Karachi 1 has won the game quarter 1 by achieving 50% seats. Keep it up all Karachi 1 colleagues as you are setting example for rest of hearty 2 team members. Surprisingly there is no one from Central. Where are you all, come up we are waiting! Now real challenge is for Hyderabad and Karachi as both are playing hard to get the maximum no. So be ready to strive more and more towards excellence. It is our commitment that we all make Rovista pride of Hearty 2.

23

Promotional PlanObjectivesQUALITATIVE OBJECTIVESTo establish GETZ as the market leader in cholesterol lowering drugs. To establish Rovista as the Universally accepted super statin.

QUANTITATIVE OBJECTIVESTo achieve the budgets of year 2007. To attain market share of approximately 3% in first year. To achieve 7th rank in statin market in first year after launch.

CURRENT SITUATION Key Fact There is a huge potential of Rovista in cholesterol lowering market. Rosuvastatin as a molecule is gaining acceptance in the market. We should strive to plan and execute quality academic activities for image building of Rovista

PROMOTIONAL STRATEGY Establish Rovista as the most superior statin in terms of both efficacy and safety. To convert the prescibers of simvastatins and atorvastatins (except Lipiget) to Rovista by highlighting superior efficacy and safety.

Product PositioningUniversally accepted super statin

COMPREHENSIVE, LONG TERM research program on rosuvastatin.10 studies have been completed & 11 studies are ongoing. Studies available show the higher efficacy of rosuvastatin over other statins.

TARGET CUSTUMERSCardiologists Physicians Diabetologists A Class GPs

24

PROMOTIONAL PLAN FOR Q4 20071. MGMs on RovistaOBJECTIVE To establish the superiority of Rovista over other statins by discussing and highlighting the results of GALAXY program studies in selected audience. TARGET AUDIENCE A class GPs, MOs of Cardio and Medical units. NO. OF DOCTORS 5-7doctors/MGM SPEAKERS Will be arranged locally or ASMD BUDGET ALLOCATION Rs. 2000/MGM MGMs SCHEDULE As discussed with ASMs South Karachi 1 Karachi 2 Hyderabad Sukkur Quetta Total No 10 8 6 4 2 30 Central Lahore Faisalabad Multan Sahiwal Gujranwala Total No 10 6 6 4 4 30 North Rawalpindi Swat Peshawar Total No 10 3 7 20

Total 80 MGMs are planned in Q3 2007.

25

Study ReprintIn Q3, we will discuss STELLAR with our doctors as we have the literature with the title of STELLAR. We are sending you reprint of this study. STELLAR stands for Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin. OBJECTIVE: The objective of this study was to compare the efficacy across dose range of rosuvastatin with atorvastatin, pravastatin and simvastatin in subjects with primary hypercholesterolaemia. RESULTS: Rosuvastatin 10-40 mg/day reduced LDL cholesterol by 46-55%, compared to 37-51% with atorvastatin 10-80 mg/day, 28-46% with simvastatin 10-80 mg/day and 20-30% with pravastatin 10-40 mg/day. So this study help us a lot in establishing the superiority of Rovista over other statins.

LITERATUREA 4 page detail aid folder STELLAR & MERCURY TRIAL

SAMPLESFor 5mg & 10mg 5mg 150cc/TM 10mg 75cc/TM

26

Model Detailing Pattern Rovista Literature Highlighting STELLAR, MERCURY ll & Safety Studies Page 1 (Title)Dear Dr today I will share some information with you about the planet Mercury. Sir Mercury is the smallest planet in the solar system and is also the closest one to Sun having distance of 36 million miles. The time which it takes to have a complete circle around the sun is called one Mercury year and is equal to 88 earth days. Dr. sb these all planets are the part of galaxy and universe and I have the Statin which is universally accepted super statin Rovista

Page 2Sir today I will discuss only 2 major studies with you first is the STELLAR STUDY. i.e. statin therapies for elevated lipid levels compared across doses to rosuvastatin. In this we have pair wise comparison of Rosuvastatin with Atorvastatin and simvastatin with same doses i.e. 10mg rosuvastatin with 10mg of Atorvastatin and simvastatin. And 20mg rosuvastatin with 20 of Atorvastatin and simvaststain. Also the same with 40 and 80mg of Rosuvastatin. Sir results show rosuvastatin is far more superior in reducing LDL Cholesterol across dose range as compared to other statins. I would also like to discuss another study MERCURY ll i.e. measuring effective reductions in cholesterol using rosuvastatin therapy. This is 16 week study which concludes that patients taking rosuvastatin significantly reduces LDL-C which is far superior than other statins. This study also shows that those patients who have switced from other statins to Rosuvaststin have a significant reduction in LDL-C as compared to patients who continue using Atorvastatin and simvastatin.

Page 3This page highlights the excellent safety and tolerability of Rosuvastatin. This study showed that there are negligible chances of myopathy with Rosuvastatin as just 0.20 incidence rate per 1000 year means only 0.2% chances of myopathy in 1000 cases. This study also highlights that Rosuvastatin maintains renal function well as compared to the other statins and similarly it is more hepatic safe when compared with other statins.

Page 4(last page)Sir the usual starting dose of Rovista is 5 or 10mg and a significant response begins within 2 weeks time. Once daily dose provides convenience to your patients.

27

Now I would like to summarize that Rovista is setting new standards, Rovista not only produces beneficial effects on key lipid parameters across the dose range but also with excellent tolerability and safety profile. Rovista is a FDA approved molecule with strong scientific evidence of galaxy program and is available in an affordable price. As you know we have Rovista the Universally Accepted Super Statin available in 3 strengths 5, 10 and 20mg. available in 9.90, 17.90 and 28.90 Rs/ tablet respectively Dr Sb I am confident that keeping in view of the benefits of Rovista you will prescribe Rovista in patients having dyslipidemias.

28